FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311572521> ?p ?o ?g. }

• W4311572521 abstract "Depressive symptoms are common in patients with Parkinson's disease and depression is a significant predictor of functional impairment, reduced quality of life and general well-being in Parkinson's disease. Despite the high prevalence of depression, evidence on the effectiveness and tolerability of antidepressants in this population is limited. The primary aim of this trial is to establish the clinical and cost effectiveness of escitalopram and nortriptyline for the treatment of depression in Parkinson's disease.This is a multi-centre, double-blind, randomised placebo-controlled trial in 408 people with Parkinson's disease with subsyndromal depression, major depressive disorder or persistent depressive disorder and a Beck Depression Inventory-II (BDI-II) score of 14 or above. Participants will be randomised into one of three groups, receiving either escitalopram, nortriptyline or placebo for 12 months. Trial participation is face-to-face, hybrid or remote. The primary outcome measure is the BDI-II score following 8 weeks of treatment. Secondary outcomes will be collected at baseline, 8, 26 and 52 weeks and following withdrawal, including severity of anxiety and depression scores as well as Parkinson's disease motor severity, and ratings of non-motor symptoms, cognitive function, health-related quality of life, levodopa-equivalence dose, changes in medication, overall clinical effectiveness, capability, health and social care resource use, carer health-related quality of life, adverse effects and number of dropouts.This trial aims to determine the effectiveness of escitalopram and nortriptyline for reducing depressive symptoms in Parkinson's disease over 8 weeks, to provide information on the effect of these medications on anxiety and other non-motor symptoms in PD and on impact on patients and caregivers, and to examine their effect on change in motor severity.ClinicalTrials.gov Identifier: NCT03652870 Date of registration - 29th August 2018." @default.
• W4311572521 created "2022-12-27" @default.
• W4311572521 creator A5001399227 @default.
• W4311572521 creator A5031103837 @default.
• W4311572521 creator A5037049771 @default.
• W4311572521 creator A5037586028 @default.
• W4311572521 creator A5051652865 @default.
• W4311572521 creator A5052356622 @default.
• W4311572521 creator A5055543220 @default.
• W4311572521 creator A5059386114 @default.
• W4311572521 creator A5060373897 @default.
• W4311572521 creator A5070050604 @default.
• W4311572521 creator A5091328388 @default.
• W4311572521 date "2022-12-12" @default.
• W4311572521 modified "2023-10-14" @default.
• W4311572521 title "Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson’s disease" @default.
• W4311572521 cites W1975905356 @default.
• W4311572521 cites W1979684199 @default.
• W4311572521 cites W1986787841 @default.
• W4311572521 cites W1996673522 @default.
• W4311572521 cites W2042158944 @default.
• W4311572521 cites W2065363088 @default.
• W4311572521 cites W2065369785 @default.
• W4311572521 cites W2074828631 @default.
• W4311572521 cites W2083924947 @default.
• W4311572521 cites W2097365507 @default.
• W4311572521 cites W2099337970 @default.
• W4311572521 cites W2101963851 @default.
• W4311572521 cites W2103019815 @default.
• W4311572521 cites W2105422294 @default.
• W4311572521 cites W2110790733 @default.
• W4311572521 cites W2128283668 @default.
• W4311572521 cites W2140374231 @default.
• W4311572521 cites W2145618858 @default.
• W4311572521 cites W2328119063 @default.
• W4311572521 cites W2420049616 @default.
• W4311572521 cites W2735307534 @default.
• W4311572521 cites W2744843428 @default.
• W4311572521 cites W2794483059 @default.
• W4311572521 cites W4200177688 @default.
• W4311572521 cites W2120932090 @default.
• W4311572521 doi "https://doi.org/10.1186/s12883-022-02988-5" @default.
• W4311572521 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36510237" @default.
• W4311572521 hasPublicationYear "2022" @default.
• W4311572521 type Work @default.
• W4311572521 citedByCount "3" @default.
• W4311572521 countsByYear W43115725212023 @default.
• W4311572521 crossrefType "journal-article" @default.
• W4311572521 hasAuthorship W4311572521A5001399227 @default.
• W4311572521 hasAuthorship W4311572521A5031103837 @default.
• W4311572521 hasAuthorship W4311572521A5037049771 @default.
• W4311572521 hasAuthorship W4311572521A5037586028 @default.
• W4311572521 hasAuthorship W4311572521A5051652865 @default.
• W4311572521 hasAuthorship W4311572521A5052356622 @default.
• W4311572521 hasAuthorship W4311572521A5055543220 @default.
• W4311572521 hasAuthorship W4311572521A5059386114 @default.
• W4311572521 hasAuthorship W4311572521A5060373897 @default.
• W4311572521 hasAuthorship W4311572521A5070050604 @default.
• W4311572521 hasAuthorship W4311572521A5091328388 @default.
• W4311572521 hasBestOaLocation W43115725211 @default.
• W4311572521 hasConcept C118552586 @default.
• W4311572521 hasConcept C126322002 @default.
• W4311572521 hasConcept C139719470 @default.
• W4311572521 hasConcept C142724271 @default.
• W4311572521 hasConcept C159110408 @default.
• W4311572521 hasConcept C162324750 @default.
• W4311572521 hasConcept C1862650 @default.
• W4311572521 hasConcept C197934379 @default.
• W4311572521 hasConcept C204787440 @default.
• W4311572521 hasConcept C27081682 @default.
• W4311572521 hasConcept C2776867660 @default.
• W4311572521 hasConcept C2778375690 @default.
• W4311572521 hasConcept C2779134260 @default.
• W4311572521 hasConcept C2779177272 @default.
• W4311572521 hasConcept C2779583969 @default.
• W4311572521 hasConcept C2779631380 @default.
• W4311572521 hasConcept C2779734285 @default.
• W4311572521 hasConcept C2779951463 @default.
• W4311572521 hasConcept C2908647359 @default.
• W4311572521 hasConcept C558461103 @default.
• W4311572521 hasConcept C71924100 @default.
• W4311572521 hasConcept C99454951 @default.
• W4311572521 hasConceptScore W4311572521C118552586 @default.
• W4311572521 hasConceptScore W4311572521C126322002 @default.
• W4311572521 hasConceptScore W4311572521C139719470 @default.
• W4311572521 hasConceptScore W4311572521C142724271 @default.
• W4311572521 hasConceptScore W4311572521C159110408 @default.
• W4311572521 hasConceptScore W4311572521C162324750 @default.
• W4311572521 hasConceptScore W4311572521C1862650 @default.
• W4311572521 hasConceptScore W4311572521C197934379 @default.
• W4311572521 hasConceptScore W4311572521C204787440 @default.
• W4311572521 hasConceptScore W4311572521C27081682 @default.
• W4311572521 hasConceptScore W4311572521C2776867660 @default.
• W4311572521 hasConceptScore W4311572521C2778375690 @default.
• W4311572521 hasConceptScore W4311572521C2779134260 @default.
• W4311572521 hasConceptScore W4311572521C2779177272 @default.
• W4311572521 hasConceptScore W4311572521C2779583969 @default.
• W4311572521 hasConceptScore W4311572521C2779631380 @default.
• W4311572521 hasConceptScore W4311572521C2779734285 @default.
• W4311572521 hasConceptScore W4311572521C2779951463 @default.

• next